

## *Why carry out this study?*

- Information detailing the experience of patients with light chain (AL) amyloidosis is very limited
- This study gathered data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care

## *What was learned from the study?*

- It can be challenging to diagnose amyloidosis; an early and correct diagnosis is essential to improve patient outcomes
- Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients
- Patients with AL amyloidosis are willing to participate in clinical trials to advance the development of well-tolerated therapies with clear treatment benefit

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by the Amyloidosis Research Consortium. Medical writing assistance for this study was provided by David Gibson, PhD, CMPP. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).